Lilly obesity pill Foundayo records 7,335 prescriptions

Eli Lilly weight-loss drug Foundayo saw 7,335 U.S. prescriptions in its fourth week. Analysts say the pill needs 22,000 weekly scripts to meet sales targets.

Xurve View
洞察:

ELI LILLY & CO recorded 7,335 prescriptions for its oral weight-loss drug Foundayo in the United States during its fourth week. The uptake lags behind the Wegovy pill from Novo Nordisk, which launched in January with a first-mover advantage. Investors view these oral treatments as expanding the weight-loss market to millions of patients, potentially countering pricing pressure on injectable treatments.

Foundayo Faces Uphill Climb to Meet Sales Targets

IUX24

IUX24 提供深度財經、經濟與投資資訊,借助 AI 挖掘全球市場中最重要的訊號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場資料、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易訊號或經紀服務。投資涉及風險,使用者在做出投資決定前應審慎評估相關資訊。